Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 1451 - 1475 of 1870 in total

Lixisenatide

Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Approved
Matched Description: … It is sold by Sanofi-Aventis under the brand name Adlyxin in the US[L763] and Lyxumia in the EU. …
Matched Mixtures name: … LYXUMIA SOLUTION FOR INJECTION IN PRE-FILLED PEN 10MCG AND 20MCG (50mcg/mL and 100mcg/mL) ... LYXUMIA SOLUTION FOR INJECTION IN PRE-FILLED PEN 10MCG AND 20MCG (50mcg/mL and 100mcg/mL) ... Soliqua SoloStar 100units/mL+33mcg/mL solution for injection in a pre-filled pen …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... insulin glargine and lixisenatide …
Matched Products: … LYXUMIA (SOLUTION FOR INJECTION 10 MCG) ... LYXUMIA (SOLUTION FOR INJECTION 20 MCG) ... Lyxumia 20mcg Solution for Injection …

Panitumumab

Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent. Panitumumab was granted FDA approval on 27 September 2006.
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … Vectibix 100mg Concentrate for Solution for Infusion ... Vectibix Concentrate for Solution for Infusion 100 mg/vial …

Benralizumab

Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R,...
Approved
Investigational
Matched Description: … , macrophages and neutrophils. ... global biologic research and development arm. ... specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Drugs for Obstructive Airway Diseases …
Matched Products: … Fasenra 30mg Solution for Injection in Pre-filled Pen ... Fasenra 30 mg solution for injection in pre-filled syringe ... FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN) …

Eravacycline

Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic...
Approved
Investigational
Matched Description: … tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and ... carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens [A38683]. ... to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and …
Matched Categories: … Antibacterials for Systemic Use ... Antiinfectives for Systemic Use …
Matched Products: … XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIAL …

Etelcalcetide

Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.
Approved
Investigational
Matched Description: … Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism ( ... Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Sex Hormones and Insulins ... Calcium Homeostasis ... Calcium-sensing Receptor Agonist ... Increased Calcium-sensing Receptor Sensitivity …
Matched Products: … Parsabiv 5mg solution for injection ... Parsabiv 2.5mg solution for injection ... Parsabiv 10mg solution for injection …

Cimicoxib

Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.
Investigational
Matched Description: … Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and …
Matched Products: … Cimalgex 30mg chewable tablets for dogs ... Cimalgex 80mg chewable tablets for dogs ... Cimalgex 8mg chewable tablets for dogs …

Canakinumab

Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy...
Approved
Investigational
Matched Description: … Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older ... part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and ... It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Matched Products: … Ilaris Powder for Solution for Injection 150mg/vial ... ILARIS 150MG POWDER FOR SOLUTION FOR INJECTION …

Tozinameran

The Pfizer-BioNTech COVID-19 vaccine (also known as BNT162b2, Tozinameran, and Comirnaty), is one of four advanced mRNA-based vaccines developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002,L15007,L36025] Comirnaty is a nucleoside modified mRNA (modRNA) vaccine encoding an optimized full-length version of the severe acute respiratory syndrome coronavirus 2...
Approved
Investigational
Matched Description: … [L26956] Fact sheets for caregivers, recipients, and healthcare providers are now available. ... Comirnaty is also approved for use as a fourth booster shot in adults 50 years of age and older. ... The Pfizer-BioNTech COVID-19 vaccine (also known as BNT162b2, Tozinameran, and Comirnaty), is one of …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Products: … COMIRNATY 10mcg Concentrate for Dispersion for Injection ... COMIRNATY (Tris/Sucrose) 30 mcg Solution for Injection …

Interferon beta-1a

Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …
Matched Products: … Rebif 22mcg/0.5ml solution for injection ... Rebif 44mcg/0.5ml solution for injection ... Rebif Solution for Injection in Cartridge 22mcg/0.5ml …

Tigecycline

Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.
Approved
Matched Description: … Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil ... Food and Drug Administration (FDA) on June 17, 2005. …
Matched Categories: … Antibacterials for Systemic Use ... Antiinfectives for Systemic Use …
Matched Products: … Tigaciv 50mg Lyophilized Powder for Concentrate for Solution for Infusion ... TIGECYCLINE SANDOZ POWDER FOR SOLUTION FOR INFUSION 50 MG PER VIAL ... TIGAR 50 (Tigecycline Powder for Solution for Infusion 50mg/Vial) …

Durvalumab

Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour...
Approved
Investigational
Matched Description: … Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint ... unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1% of tumour cells and ... ] and either [carboplatin] or [cisplatin] as first-line treatment of patients with extensive-stage small …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … IMFINZI CONCENTRATE FOR SOLUTION FOR INFUSION 50 MG/ML ... IMFINZI CONCENTRATE FOR SOLUTION FOR INTRAVENOUS INFUSION 50 MG/ML …

Gemtuzumab ozogamicin

Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody [FDA Label]. The antibody is specifically...
Approved
Investigational
Matched Description: … It is also indicated for the treatment of patients aged 2 years and older with CD33-positive AML who ... By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and ... with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/VIAL …

Inotuzumab ozogamicin

Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide. The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly releases N-acetyl-gamma-calicheamicin dimethylhydrazide, which produces cytotoxic effects. Inotuzumab ozogamicin was first...
Approved
Investigational
Matched Description: … [A20352] The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly ... [A20352] Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL …

Deferoxamine

Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Approved
Investigational
Matched Description: … It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. …
Matched Products: … Desferal 500mg Powder for Solution for Injection ... Deferoxamine Mesylate for Injection ... DBL DESFERRIOXAMINE MESYLATE FOR INJECTION BP 500 mg/vial …

Decitabine

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis.[A215082, A215092] Among treatment options, nucleoside analogues such as...
Approved
Investigational
Matched Description: … approved by the FDA for the treatment of MDS on February 5, 2006. ... presentation, including neutropenia and thrombocytopenia. ... and related downstream therapeutic benefits. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …
Matched Products: … DACOGEN (Decitabine) 50 mg Powder for Concentrate for Solution for Infusion ... Redtibin (Decitabine) Powder for Injection 50mg/vial …

Daunorubicin

A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
Approved
Matched Description: … A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others ... , used in treatment of leukemia and other neoplasms. …
Matched Salts name: … Daunorubicin citrate …
Matched Categories: … Anthracyclines and Related Substances ... Antineoplastic and Immunomodulating Agents ... cytarabine and daunorubicin ... Cytotoxic Antibiotics and Related Substances …
Matched Products: … DAUNOCIN FOR INJ ... DAUNOCIN FOR INJECTION 20 mg/vial ... DAUNOBLASTINA FOR INJECTION 20 mg/vial …

Atosiban

Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. Atobisan was developed by the Swedish...
Approved
Investigational
Matched Description: … Atosiban is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant ... Atosiban is an inhibitor of the hormones oxytocin and vasopressin. ... Although initial studies suggested it could be used as a nasal spray and hence would not require hospital …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Genito Urinary System and Sex Hormones ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Products: … TRACTOCILE 7.5MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION ... TRACTOCILE (7.5 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION) ... TRACTOCILE 7.5MG/ML,SOLUTION FOR INJECTION …

Beclomethasone dipropionate

Beclomethasone dipropionate is a second-generation synthetic corticosteroid and diester of beclomethasone, which is structurally similar to dexamethasone. It is a prodrug of an active metabolite beclomethasone 17-monopropionate (17-BMP) which acts on the glucocorticoid receptor to mediates its therapeutic action. Beclomethasone dipropionate itself posesses weak glucocorticoid receptor binding affinity and is...
Approved
Investigational
Matched Description: … [A179839] Formulations for oral inhalation, intranasal, and topical use are available for beclomethasone ... Beclomethasone dipropionate is a second-generation[A179842] synthetic corticosteroid and diester of beclomethasone ... later in a dry powder inhaler and an aqueous nasal spray. …
Matched Mixtures name: … Ibicar S (Salbutamol 100 mcg/actuation and Beclometasone 50 mcg/actuation) Pressurised Inhalation …
Matched Categories: … Alimentary Tract and Metabolism ... Corticosteroids for inhalation use ... beclometasone and antibiotics ... formoterol and beclometasone ... salbutamol and beclometasone …
Matched Products: … BECOTIDE FORTE ... BEKLAZON FORT KREM, 5 G ... BEKLAZON FORT KREM, 15 G …

Guselkumab

Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in...
Approved
Investigational
Matched Description: … In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological ... market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis. ... Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Skin and Mucous Membrane Agents …
Matched Products: … TREMFYA 100MG/ML SOLUTION FOR INJECTION ... Tremfya One-Press 100mg/ml Solution for Injection ... TREMFYA SOLUTION FOR INJECTION IN PRE-FILLED PEN 100MG/ML …

Emicizumab

Emicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X. The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable...
Approved
Investigational
Matched Description: … Emicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017. ... Ltd. and co-developed with Roche and Genentech.[L1015] ... a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Blood and Blood Forming Organs …
Matched Products: … HEMLIBRA 30MG/ML SOLUTION FOR INJECTION ... HEMLIBRA 150MG/ML SOLUTION FOR INJECTION ... HEMLIBRA SOLUTION FOR INJECTION 30MG/ML …

Insulin glulisine

Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the...
Approved
Matched Description: … Type 1 and Type 2 Diabetes. ... and proteolysis among many other functions. ... tissues such as the liver, fat cells, and skeletal muscle. …
Matched Categories: … Insulins and Analogues for Injection, Fast-Acting ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Products: … APIDRA 100 Units/ml Solution for Injection in vial ... APIDRA 100 U/ML- SOLUTION FOR INJECTION IN VIAL ... Apidra SoloStar 100 Units/ml Solution for injection in a pre-filled pen …

Atracurium besylate

A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.
Approved
Matched Description: … Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for …
Matched Products: … Atracurium - (for Single Dose ) ... Atracurium Kabi 10mg/ml Solution for Injection USP ... ATRACURIUM LABATEC IV SOLUTION FOR INJECTION 10MG/ML …

Ixabepilone

Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is...
Approved
Investigational
Matched Description: … Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Cytotoxic Antibiotics and Related Substances …
Matched Products: … IXEMPRA FOR INJECTION 15 MG ... IXEMPRA (FOR INJECTION 15 MG) ... IXEMPRA FOR INJECTION 45 MG …

Methoxy polyethylene glycol-epoetin beta

Methoxy polyethylene glycol-epoetin beta is a chemically synthesised Erythropoiesis Stimulating Agent (ESA) with a longer half-life than erythropoietin. ESA is used to increase synthesis of red blood cells to treat chronic kidney disease associated anemia.
Approved
Matched Categories: … Amino Acids, Peptides, and Proteins ... Blood and Blood Forming Organs ... Intercellular Signaling Peptides and Proteins …
Matched Products: … Mircera Solution for Injection 100mcg/0.3ml (Pre-filled Syringe) ... Mircera Solution for Injection 75mcg/0.3ml (Pre-filled Syringe) ... Mircera Solution for Injection 50mcg/0.3ml (Pre-filled Syringe) …

Clofarabine

Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic...
Approved
Investigational
Matched Description: … It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. ... Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been ... type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …
Matched Products: … EVOLTRA 1 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION ... NUCLOFAR Clofarabine 1mg/mL Concentrate for Solution for Infusion ... Evoltra Concentrate Solution for Infusion 1mg/ml …
Displaying drugs 1451 - 1475 of 1870 in total